Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral therapeutics specifically designed to treat cancers and premalignant infections caused by Human Papillomavirus (HPV).
HPV can cause cancer
Millions of men and women globally have acquired an HPV infection, a portion of which persist and progress to cancer. An estimated 630,000 HPV-related malignancies are diagnosed each year, amounting to 5% of the cancer burden worldwide.
Most cervical and oral cancers are caused by HPV
HPV causes nearly all cervical and the majority of oropharyngeal cancers. Existing treatment options include surgery, radiation and chemotherapy, all with significant side effects.
HPV vaccine does not impact existing infections
The HPV vaccine prevents new infections but does not treat the millions of existing infections that can progress to cancer.